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thetic grafts may overcome the shortcomings of other 
graft options.
Cerafix® Dura Substitute (Acera Surgical, Inc., St. 
Louis, MO) is a unique non-biologic dura substitute 
produced via nanofiber electrospinning which provides 
impressive strength, handling, and suturability while 
mollifying local inflammation [4,5]. This biodegradable 
poly (lactic-co-glycolic acid)/polydioxanonematerial is 
synthesized into a form that mimics native extracellu-
lar matrix to improve tissue in growth, neoduralization, 
and watertight closure. In preclinical testing, Cerafix® 
demonstrated effective repair of induced dural defects 
and successful prevention of cerebrospinal fluid leakage 
without infection or damage to underlying cortical tissue 
[5]. Compared to DuraMatrix™ (Stryker, Inc., Kalamazoo, 
MI), a popular collagen-based dura substitute from bo-
vine dermis or calcaneal tendon, Cerafix® exhibited in-
creased neoduralization, fewer cortical adhesions, and 
less inflammation/fibrosis in a rabbit duraplasty model 
[5]. Compared to DuraGen Plus™ (Integra LifeSciences, 
Inc., Plainsboro, NJ), another commercially available xe-
nogenic dura substitute, Cerafix® demonstrated superi-
or tensile and burst strengths [6].
In this study, we performed a retrospective case se-
ries to evaluate the efficacy of a novel, fully synthetic 
dura substitute currently in clinical use within neurosur-
gical operating facilities at Barnes Jewish Hospital/Wash-
ington University School of Medicine. The clinical out-
comes and surgeon experiences of these cases confirm 
that Cerafix® Dura Substitute is a superior option in the 
arsenal of available dura substitutes for neurosurgery.
Case Descriptions
Data on three unique individuals who underwent 
Abstract
Background: Despite the range of available dura substi-
tutes, limitations such as harvest site morbidity and graft 
degradation still exist. As such, there is a need for an opti-
mized dura substitute with superior safety and mechanical 
properties than currently available products.
Methods: A retrospective case series was performed to 
evaluate the efficacy of a novel, fully synthetic dura substi-
tute. Clinical outcomes (e.g. infectious, reoperation rates, 
cerebrospinal fluid leak) and surgeon experiences with the 
dura substitute intraoperatively were collected. All methods 
were approved by the Institutional Review Board at Wash-
ington University School of Medicine.
Conclusion: This study explored the clinical performance 
of a fully synthetic nanofabricated dura substitute. Case 
analysis demonstrated none required reoperation or had 
clinical evidence of CSF leakage, pseudomeningocele, or 
meningeal disease after surgery. Results from the physician 
survey indicated that this dura substitute offered benefits in 
tensile strength appropriate for a variety of neurosurgical 
procedures.
Keywords






Dural substitutes are routinely used in neurosurgi-
cal procedures that require disruption of the dura ma-
ter to access deeper tissue [1]. A repertoire of materi-
als is available to repair these defects including auto-
graft, xenograft, and recently non-biologic synthetics. 
Despite this diversity, limitations exist in using auto-
graft (e.g. poor availability and harvest site morbidity) 
or xenograft (e.g. foreign body inflammatory reactions 
and graft degradation) [2,3]. Exploration and optimi-
zation of the safety and mechanical properties of syn-
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smoking history. Physical examination was unremark-
able, but brain MRI revealed an enhancing mass in the 
right parietal lobe with large surrounding edema ex-
tending into right frontal and temporal lobes as well as 
along the right internal capsule. There was also approx-
imately 5 mm of leftward midline shift.
He underwent a right frontotemporal craniotomy 
with microsurgical resection of the tumor. After resec-
tion, the dura was reapproximated with nylon sutures. 
A patch of Cerafix® Dura Substitute was sewn in place 
followed by an onlay of Cerafix® over the durotomy line 
sealed with Tisseel™ fibrin sealant. Postoperative im-
agingshowed expected postsurgical changes including 
resolution of midline shift without hydrocephalus. At 
3-month follow up, the patient had no evidence of CSF 
leakage, pseudomeningocele, or meningitis.
Case 2
A 57-year-old man with dementia presented with 
confusion and decreased level of consciousness after a 
forward fall and subsequent forehead trauma. Medical 
history was significant for pituitary adenoma status post 
resection and radiotherapy with secondary adrenal in-
sufficiency, hypothyroidism, and hypogonadism. During 
physical examination, he was unable to hold conversa-
tion or follow commands. Noncontrast head CT revealed 
a 7-mm thick subdural hematoma (SDH) overlying the 
right cerebral convexity.
Craniotomy for hematoma evacuation was performed. 
After copious irrigation, the dura was repaired via inter-
rupted nylon sutures above which a piece of Cerafix® Dura 
Substitute was placed and fixed to the bone flap via cen-
tral tack-up sutures. Postoperative head CT showed inter-
val evolution of the SDH and reduced midline shift with 
some effacement of the right lateral ventricle. The patient 
expired one month later from respiratory failure and un-
derlying endocrinopathy. No clinical evidence of CSF leak-
age or infection was noted before then.
Case 3
A 66-year-old man with history of a fourth ventricle 
ependymoma status post-resection and chemoradio-
therapy presented with weeks of worsening diplopia, 
episodic confusion, and overall visual decline. Physical 
examination revealed inducible diplopia on extreme lat-
eral gaze bilaterally. Preoperative imaging demonstrat-
ed a trilobed peripherally enhancing irregular mass in 
the left temporooccipital region with central necrosis 
and associated diffusion restriction. Extension to the 
splenium was also noted.
The patient underwent craniotomy and microsurgi-
cal resection of the left occipital mass later determined 
to be glioblastoma multiforme. Dura defects were 
closed using Vicryl® (Ethicon, Inc., Bridgewater, NJ) su-
tures and an onlay of Cerafix® Dura Substitute. Postop-
erative MRI showed T1 hyperintensity in the resection 
neurosurgery in May 2017 were collected via medi-
cal record review. Data points included patient age, 
patient sex, preoperative medical history, imaging 
findings, primary diagnosis, and postoperative clinical 
outcomes i.e. incidence of cerebrospinal fluid (CSF) 
leakage, persistent fluid collection, infection, and reop-
eration within three months of the surgery. Surgeon ex-
periences with the synthetic dura substitute were doc-
umented immediately following respective procedures. 
Responses were quantified and are reported in Table 1. 
All methods were approved by the institutional review 
board (IRB) at Washington University School of Medi-
cine.
Case 1
A 63-year-old man with hypertension, hyperlipid-
emia, and a solitary pulmonary nodule presented with 
two to three weeks of declining fine motor skills and 
morning headaches. The patient had 1-pack per day 























Any dural defect 2
Will you use Cerafix® for future cases?b
Yes 5
No 0




aMultiple answers were acceptable for this question; bOnly one 
answer was acceptable for this question.
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of Defense and National Institutes of Health. MR MacE-
wan has equity interest in Acera Surgical, Inc. All other 
authors have no competing interests to declare.
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cavity consistent with residual blood products. There 
was patchy enhancement in the splenium suspicious for 
residual tumor. At 3-month follow up, the patient had 
completed chemotherapy and craniospinal radiation. 
Symptomatically, he had returned to neurological base-
line although brain MRI continued to show marginal en-
hancement of the resection cavity concerning for tumor 
progression. He had no persistent fluid collections, CSF 
leaks, or clinical signs of infection over this period. 
Conclusions
In their review of available dural grafting materials, 
Berjano, et al. proposed characteristics of the ideal dura 
substitute: watertight closure, low antigenicity/tissue 
toxicity, free from potential risk of infection, easy han-
dling, and availability [7]. Although options for substi-
tutes exist, they are mostly limited to autogenic and xe-
nogenic materials with poor availability, risk of disease 
transmission, or higher antigenicity.
Autografts are obtained from pericranial tissue or 
tendinous fascia lata. Although they do not elicit sig-
nificant inflammation, their use is limited by host site 
morbidity and larger dural defect areas [5]. Allografts 
from cadaveric dura are more available but portend 
serious risk of infection [8,9]. Xenografts from native 
bovine or porcine tissues offer a similar feel to human 
dura as well as robust cellular infiltration and angiogen-
esis [3,5]. However, graft degradation is known to occur 
prematurely resulting in weak tissue over the dural de-
fect [3,5]. The tradeoff between mechanical propertie-
sand resorption ability in addition to the risk of zoonosis 
and allergic reactions restricts their routine application 
[3,10]. Effectiveness of other synthetic grafts (e.g. Pre-
clude™ and Ethisorb™ dura substitutes) is limited to 
preclinical testing where they often do not uphold simi-
lar mechanical properties [11].
This study explored the clinical performance of a ful-
ly synthetic nanofabricated dura substitute to optimize 
critical dura substitute properties. Analysis of patient 
outcomes showed that none required reoperation or 
had clinical evidence of CSF leakage, pseudomeningo-
cele, or meningeal pathology. The median length of hos-
pital stay after surgery was 4 days. While this dura sub-
stitute was examined in the adult population, its utility 
could be expanded to include pediatric cases as well. 
Further studies are required. Results from the physician 
survey indicated that Cerafix® was mostly easier to use, 
offered benefits in tensile strength, and appropriate for 
a range of surgical procedures/locations (Table 1) [12]. 
These clinical observations and surgeon experiences 
support the use of Cerafix® Dura Substitute in the neu-
rosurgical arena.
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